Merck: adjusted net income to increase fivefold by 2025

(CercleFinance.com) - Merck reports sales of $64.
16 billion for 2024, up 7% on 2023 (or +10% at constant exchange rates), driven in particular by Keytruda sales, up 18% to $29.5 billion.

Robert M. Davis, Merck's Chairman and CEO, also highlights 'the successful launch of WINREVAIR and the solid performance of the Animal Health business'.

On an adjusted basis, net income for the year came to $19.44 billion, a 5-fold increase on the previous year ($3.83 billion), giving adjusted EPS of $7.65 versus $1.51.

In Q4, sales were $15.6 billion, up 7% (+9% at constant exchange rates), with net income of $4.37 billion (vs. $66 million a year earlier) and adjusted EPS of $1.72 (vs. $0.03 a year earlier).

For 2025, Merck is targeting worldwide sales of between $64.1 billion and $65.6 billion and adjusted EPS of between $8.88 and $9.03.

Copyright (c) 2025 CercleFinance.com. All rights reserved.